Pediatric thrombosis

Pediatric Clinics of North America

Volumn 49, Issue 6, 2002, Pages 1257-1283

  Hoppe, Carolyn ^a   Matsunaga, Alison ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; ENOXAPARIN; ESTROGEN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; ORAL CONTRACEPTIVE AGENT; PENTASACCHARIDE; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTHROMBIN; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; AUTOIMMUNE DISEASE; CENTRAL VENOUS CATHETER; CHILD; CLINICAL FEATURE; DEEP VEIN THROMBOSIS; DIAGNOSTIC APPROACH ROUTE; DYSFIBRINOGENEMIA; FULMINATING PURPURA; HUMAN; HYPERHOMOCYSTEINEMIA; INCIDENCE; INFECTION; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; NEPHROTIC SYNDROME; OSTEOPENIA; PHLEBITIS; PREGNANCY; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK FACTOR; STROKE; THROMBOCYTOPENIA; THROMBOSIS; VEIN THROMBOSIS;

CHILD; CHILD, PRESCHOOL; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; RISK FACTORS; THROMBOSIS;

EID: 0036978885     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-3955(02)00092-5     Document Type: Review

References (179)

1. Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 2000;47(6):763-6.
2. Nowak-Gottl U, Kosch A, Schlegel N. Thromboembolism in newborns, infants and children. Thromb Haemost 2001;86(1):464-74.
3. deVeber G, Andrew M. Cerebral sinovenous thrombosis in children. N Engl J Med 2001; 345(6):417-23.
4. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119(Suppl 1):64S-94S.
5. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994;83(5):1251-7.
6. Streif W, Andrew ME. Venous thromboembolic events in pediatric patients. Diagnosis and management. Hematol Oncol Clin N Am 1998;12(6):1283-312.
7. Nowak-Gottl U, von Kries R, Gobel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Arch Dis Child Fetal Neonatal Ed 1997;76(3):F163-7.
8. Andrew M. Relevance to newborns and infants. In: Nathan D, Orkin SH, editors. Nathan and Oski's hematology of infancy and childhood. 5th edition. Philadelphia: WB Saunders; 1998. p. 155-7.
9. Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics 1995;96(5 Pt 1):939-43.
10. Heller C, Schobess R, Kurnik K, et al. Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors - a multicentre case-control study. For the Childhood Thrombophilia Study Group. Br J Haematol 2000;111(2):534-9.
11. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992;80(8):1998-2005.
12. Manco-Johnson M. The infant and child with thrombosis. In: Goodnight S, Hathaway W, editors. Disorders of hemostasis and thrombosis: a clinical guide. 2nd edition. New York: McGraw-Hill; 2001. p. 325-38.
13. Zell L, Kindermann W, Marschall F, Scheffler P, Gross J, Buchter A. Paget-Schroetter syndrome in sports activities - case study and literature review. Angiology 2001;52(5):337-42.
14. Nightingale A, Lawrenson R, Simpson E, Williams T, MacRae K, Farmer R. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives. Eur J Contracept Reprod Health Care 2000;5(4):265-74.
15. Jick H, Kaye J, Vasilakis-Scaramozza C, Jick S. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: Cohort and case-control analysis. BMJ 2000;321:1190-5.
16. Andrew M. Congenital prothrombotic disorders: presentation during infancy and childhood. In: Andrew MMP, Brooker L, editors. Thromboembolic complications during infancy and childhood. Hamilton, Ontario: BC Decker; 2000. p. 47-110.
17. Dahlback B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995;85(3):607-14.
18. Rosendaal M, Mayen A, de Koning A, Dunina-Barkovskaya T, Krenacs T, Ploemacher R. Does transmembrane communication through gap junctions enable stem cells to overcome stromal inhibition? Leukemia 1997;11(8):1281-9.
19. Lane D, Manucci P, Bauer K, et al. Inherited thrombophilia: part I. Thromb Haemost 1996;76:651-62.
20. Nowak-Gottl U, Junker R, Kreuz W, et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001;97(4):858-62.
21. Dolan G, Preston F. Familial plasminogen deficiency and thromboembolism. Fibrinolysis 1988;2:26-34.
22. Engesser L. Elevated plasminogen activator inhibitor (PAD(PAI) as cause of thrombophilia? A study in 203 patients with familial or sporadic venous thrombophilia. Thromb Haemost 1989;62(2):673-80.
23. Ridker P. Baseline fibrinolytic state and the risk of future venous thromboembolism. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation 1992;85:1822-7.
24. Sartori M. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thromb Haemost 1998;80:956.
25. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PAI1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis [see comments]. Lancet 1997;349(9049):385-8.
26. Bertina R, van der Linden I, Engesser L. Hereditary heparin cofactor II deficiency and the risk of development of thrombosis. Thromb Haemost 1987;57:196-200.
27. Tran TH, Marbet GA, Duckert F. Association of hereditary heparin co-factor II deficiency with thrombosis. Lancet 1985;2(8452):413-4.
28. Weisdorf DJ, Edson JR. Recurrent venous thrombosis associated with inherited deficiency of heparin cofactor II. Br J Haematol 1991;77(1):125-6.
29. von Depka M, Nowak-Gottl U, Eisert R, et al. Increased lipoprotein(a) levels as an independent risk factor for venous thromboembolism. Blood 2000;96(10):3364-8.
30. O'Donnell J, Laffan M. Elevated plasma factor VIII levels - a novel risk factor for venous thromboembolism. Clin Lab 2001;47(1-2):1-6.
31. Nowak-Gottl U, Junker R, Hartmeier M, et al. Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. Circulation 1999;100(7):743-8.
32. Dahlback B, Carlsson M, Svensson P. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci 1993;90(1004):987-8.
33. Rees D, Cox M, Clegg J. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
34. Rosendaal FR, Koster T, Vandenbroucke J, Reitsma P. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-8.
35. Ridker P, Miletich J, Henneckens C, Buring J. Ethnic distribution of factor V Leiden in 4047 men and women. JAMA 1997;277:1305-7.
36. Zoller B, Hillarp A, Bemtorp E, Dahlback B. Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis. Annu Rev Med 1997; 48:45-58.
37. Simioni P, Sanson BJ, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999;81(2):198-202.
38. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999;82(2):610-9.
39. Debus O, Koch HG, Kurlemann G, Strater R, Vielhaber H, Weber P, et al. Factor V Leiden and genetic defects of thrombophilia in childhood porencephaly. Arch Dis Child Fetal Neonatal Ed 1998;78:121-4.
40. Nelson K, Dambrosia JM, Grether JK, Phillips TM. Neonatal cytokines and coagulation factors in children with cerebral palsy. Ann Neurol 1998;44:665-75.
41. Gruppo R, Giueck C, Wall E. Legg-Perthes disease in three siblings, two heterozygous and one homozygous for the factor V Leiden mutation. J Pediatr 1998;132:885-8.
42. Poort S, Rosendahl F, Reitsma P, Bertina R. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
43. Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CR. The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population. Br J Haematol 1997; 98(2):353-5.
44. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965;13:516-7.
45. Lane DA, Bayston T, Olds RJ, et al. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997; 77(1):197-211.
46. Triplett D. Antithrombin deficiency. In: Goodnight S, Hathaway W, editors. Diagnosis of hemostasis and thrombosis: a clinical guide. Second edition. New York: McGraw-Hill; 2001. p. 359-65.
47. deVeber G, Monagle P, Chan A, et al. Prothrombotic disorders in infants and children with cerebral thromboembolism. Arch Neurol 1998;55(12):1539-43.
48. Tait R, Walker I, Reitsma P, et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995;73:87-93.
49. Van Boven H, Reitsma P, Rosendahl F. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996;57:417-21.
50. Uttenreuther-Fischer M, Ziemer S, Gaedicke G. Resistance to activated protein C (APCR): reference values of PCS-ratios for children. Thromb Haemost 1996;76:813-21.
51. Rezende S, Lane D, Zoller B, et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2002;97(4):858-62.
52. Bucciarelli P, Rosendaal F, Tripodi A, et al. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol 1999;19(4):1026-33.
53. Horowitz I, Galvis A, Gomperts E. Arterial thrombosis and protein S deficiency. J Pediatr 1992; 121:934-7.
54. Israels S, Seshia S. Childhood stroke associated with protein C or S deficiency. J Pediatr 1987; 111:5624.
55. Mannucci P, Tripodi A, Bertina R. Protein S deficiency associated with "juvenile" arterial and venous thromboses. Thromb Haemost 1986;55:440.
56. De Stefano V, Leone G, Ferrelli R. Severe deep vein thrombosis in a 2 year old child with protein S deficiency. Thromb Haemost 1987;58:1089.
57. Pegelow C, Ledford M. Severe protein S deficiency in a newborn. Pediatrics 1992;89:674-5.
58. Mahasandana C, Veerakul G, Tanphaichitr VS, Suvatte V, Opartkiattikul N, Hathaway WE. Homozygous protein S deficiency: 7 year follow-up. Thromb Haemost 1996;76:1122-3.
59. de Franchis R, Fermo I, Mazzola G, Sabasfio G. Contribution of the cystathionine beta-synthase gene (844ins68) polymorphism to the risk of early-onset venous and arterial occlusive disease and of fasting hyperhomocysteinemia. Thromb Haemost 2000;84:576-82.
60. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase [letter]. Nat Genet 1995;10(1):111-3.
61. Balasa V, Gruppo R, Guieck C. The relationship of mutations in the MTHFR, prothrombin, and PAI-1 in children and adults. Thromb Haemost 1999;81:739-44.
62. Boushey C, Beresford S, Omehn G, Motulsky A. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing tonic? acid intakes? JAMA 1995;274:1049-57.
63. McColl M, Chalmers E, Thomas A, et al. Factor V Leiden, prothrombin 20210A and the MTHFR C677T mutations in childhood stroke. Thromb Haemost 1999;81:690-4.
64. Peng D, Zhao S, Wang J. Lipoprotein(a) and lipoprotein E4 as independent risk factors for ischaemic stroke. J Cardiovasc Risk 1998;6:1-6.
65. Mosesson M. Dysfibrinogenemia and thrombosis. Semin Thromb Hemost 1999;25(11):311-9.
66. Duga S, Asselta R, Santagostino E, et al. Missense mutations in the human beta fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion. Blood 2000;95(4):1336-41.
67. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995;73(1):151-61.
68. Mosesson MW, Siebenlist KR, Hainfeld J, et al. The relationship between the fibrinogen D domain self-association/cross-linking site (gammaXL) and the fibrinogen Dusart abnormality (Aalpha R554C-albumin): clues to thrombophilia in the "Dusart syndrome". J Clin Invest 1996;97(10):2342-50.
69. Furlan M, Steinmann C, Jungo M, et al. A frameshift mutation in Exon V of the A alpha-chain gene leading to truncated A alpha-chains in the homozygous dysfibrinogen Milano III. J Biol Chem 1994;269(52):33129-34.
70. Di Minno G, Martinez J, Cirillo F, et al. A role for platelets and thrombin in the juvenile stroke of two siblings with defective thrombin-adsorbing capacity of fibrin(ogen). Arterioscler Thromb 1991;11(4):785-96.
71. Andrew M, Marzinotto V, Pencharz P, et al. A cross-sectional study of catheter-related thrombosis in children receiving total parenteral nutrition at home. J Pediatr 1995;126(3):358-63.
72. Massicotte MP, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. J Pediatr 1998;133(6):770-6.
73. Hausler M, Hubner D, Delhaas T, Muhler EG. Long term complications of inferior vena cava thrombosis. Arch Dis Child 2001;85(3):228-33.
74. Prandoni P, Polistena P, Bemardi E, et al. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med 1997;157(1):57-62.
75. Kim J, Lee Y, Kim S, Lee S, Lim M, Kim H. Does umbilical vein catheterization lead to portal venous thrombosis? Prospective evaluation in 100 neonates. Radiology 2001;219(3):645-50.
76. Joumeycake J, Quinn C, Miller K, Zajac J, Buchanan G. Catheter-related deep venous thrombosis in children with hemophilia. Blood 2001;98(6):1727-31.
77. Lee T, von Scheven E, Sandborg C. Systemic lupus erythematosus and antiphospholipid syndrome in children and adolescents. Curr Opin Rheumatol 2001;13(5):415-21.
78. Hansen KE, Kong DF, Moore KD, Ortel TL. Risk factors associated with thrombosis in patients with antiphospholipid antibodies. J Rheumatol 2001;28(9):2018-24.
79. Yuen S, Lau K, Steinberg A, Grattan-Smith P, Hodson E. Intracranial venous thrombosis and pulmonary embolism with antiphospholipid syndrome in systemic lupus erythematosus. J Paediatr Child Health 2001;37(4):405-8.
80. Triplett DA. Evaluation of the minimally prolonged APTT: Passovoy factor or lupus anticoagulant? J Pediatr Hematol Oncol 1996;18(3):247-8.
81. Triplett DA. Lupus anticoagulants: diagnostic dilemma and clinical challenge. Clin Lab Sci 1997;10(4):223-8.
82. Nojima J, Kuratsune H, Suehisa E, et al. Anti-prothrombin antibodies combined with lupus anti-coagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus. Br J Haematol 2001;114(3):647-54.
83. Wahl D, Guillemin E, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus. A meta-analysis. Lupus 1997;6:467-73.
84. de Groot P, Horbach D, Derksen R. Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. Lupus 1996;5:488-93.
85. Lanthier S, Lindsay S, Mitchell L, et al. Anticardiolipin antibodies are associated with cardioembolic stroke but do not predict recurrent cerebral ischemia in children [abstract]. Neurology 2001;S3:56.
86. Zauber NP, Sabbath-Solitare M, Rajoria G, Mogan G. Factor V Leiden mutation is not increased in patients with inflammatory bowel disease. J Clin Gastroenterol 1998;27(3):215-6.
87. Radke PW, Schwarz ER, Groesdonk H, Graf J, Janssens U. Thrombosis in Behcet's disease: report of a case followed by a systematic review using the methodology of evidence-based medicine. J Thromb Thrombolysis 2001;11(2):137-41.
88. Ko SH, Kang SK, Lee SK, Song HS. Massive thrombosis after central venous catheterization in a patient with previously undiagnosed Behcet's disease. J Korean Med Sci 2001;16(6):814-6.
89. Ertenli I, Kiraz S, Celik IC, et al. Changes in the concentration and distribution of tissue factor pathway inhibitor in Behcet's disease and systemic lupus erythematosus: effect on the prethrombotic state. Ann Rheum Dis 2001;60(12):1149-51.
90. Grip O, Svensson PJ, Lindgren S. Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol 2000;35(6):619-23.
91. Oldenburg B, Fijnheer R, van der Griend R, vanBerge-Henegouwen GP, Koningsberger JC. Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications? Am J Gastroenterol 2000;95(10):2825-30.
92. Novacek G, Miehsler W, Kapiotis S, Katzenschlager R, Speiser W, Vogelsang H. Thromboembolism and resistance to activated protein C in patients with inflammatory bowel disease. Am J Gastroenterol 1999;94(3):685-90.
93. Nowak-Gottl U, Heinecke A, von Kries R, Nurnberger W, Munchow N, Junker R. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 2001;103(3):165-72.
94. Nowak-Gottl U, Wermes C, Junker R, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999;93(5):1595-9.
95. Dreyfus M. Thrombotic risk in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2001;18(4):233-4.
96. Knofler R, Siegert E, Lauterbach I, et al. Clinical importance of prothrombotic risk factors in pediatric patients with malignancy - impact of central venous lines. Eur J Pediatr 1999; 158(Suppl 3):S147-50.
97. Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000;84(5):805-10.
98. Citak A, Emre S, Sairin A, Bilge I, Nayir A. Hemostatic problems and thromboembolic complications in nephrotic children. Pediatr Nephrol 2000;14(2):138-42.
99. Abella E. Hemostatic problems associated with renal disease. Int J Pediatr Hematol Oncol 1994;1:43-51.
100. Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal disease. Kidney Int 1994;46(2):287-96.
101. Andrew M, Brooker LA. Hemostatic complications in renal disorders of the young. Pediatr Nephrol 1996;10(1):88-99.
102. Andrew M, Montgomery RR. Acquired disorders of hemostasis. In: Nathan D, Orkin SH, editors. Nathan and Oski's hematology of infancy and childhood. 5th edition. Philadelphia: W.B. Saunders; 1998. p. 1677-717.
103. Schnaper HW. Antithrombin III, protein S, and coagulation in the nephrotic syndrome. Pediatr Nephrol 2001;16(1):98.
104. Waselenko J, Nace M, Alving B. Women with thrombophilia: assessing the risks for thrombosis with oral contraceptives or hormone replacement therapy. Semin Thromb Hemost 1998; 24(Suppl 1):33-9.
105. Rosendaal F, Helmerhorst F, Vandenbroucke J. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 2002;22(2):201-10.
106. Ginsberg JS. Thromboembolism and pregnancy. Thromb Haemost 1999;82(2):620-5.
107. Ginsberg JS, Turpie AG. Thromboembolism and pregnancy. Int Angiol 2001;20(2):103-9.
108. Bonnar J, Green R, Norris L. Perinatal aspects of inherited thrombophilia. Semin Thromb Hemost 1999;25(5):481-5.
109. Aburahma AF, Mullins DA. Endovascular caval interruption in pregnant patients with deep vein thrombosis of the lower extremity. J Vasc Surg 2001;33(2):375-8.
110. Partsch H. Therapy of deep vein thrombosis with low molecular weight heparin, leg compression and immediate ambulation. Vasa 2001;30(3):195-204.
111. Josephson C, Nuss R, Jacobson L, et al. The varicella-autoantibody syndrome. Pediatr Res 2001;50(3):345-52.
112. Levin M, Eley BS, Louis J, Cohen H, Young L, Heyderman RS. Postinfectious purpura fulminans caused by an autoantibody directed against protein S. J Pediatr 1995; 127(3):355-63.
113. Manco-Johnson MJ, Nuss R, Key N, et al. Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis. J Pediatr 1996;128(3):319-23.
114. Kurugol Z, Vardar F, Ozkinay F, Kavakli K, Ozkinay C. Lupus anticoagulant and protein S deficiency in otherwise healthy children with acute varicella infection. Acta Paediatr 2000; 89(10):1186-9.
115. Sullivan P, Dworkin M, Jones J, Hooper W. Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Disease Project. AIDS 2000;14(3):321-4.
116. Abuaf N, Laperche S, Rajoely B, et al. Autoantibodies to phospholipids and to the coagulation proteins in AIDS. Thromb Haemost 1997;77(5):856-61.
117. Hagelskjaer Kristensen L, Prag J. Human necrobacillosis, with emphasis on Lemierre's syndrome. Clin Infect Dis 2000;31(2):524-32.
118. Turay U, Erdogan Y, Ergun P, Biber C, Ciftei B, Ayaz A. Lemierre's syndrome. Respirology 2001;6(2):171-3.
119. David M, Andrew M. Venous thromboembolic complications in children. J Pediatr 1993; 123(3):337-46.
120. Monagle P, Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in children. Chest 2001;119(Suppl 1):344S-70S.
121. Cogo A, Lensing AW, Prandoni P, Hirsh J. Distribution of thrombosis in patients with symptomatic deep vein thrombosis. Implications for simplifying the diagnostic process with compression ultrasound. Arch Intern Med 1993;153(24):2777-80.
122. Kraaijenhagen RA, Lensing AW, Lijmer JG, et al. Diagnostic strategies for the management of patients with clinically suspected deep-vein thrombosis. Curr Opin Pulm Med 1997; 3(4):268-74.
123. Andrew M, de Veber G. Pediatric thromboembolism and stroke protocols. Hamilton, Ontario: B.C. Decker; 1997.
124. deVeber GA, MacGregor D, Curtis R, Mayank S. Neurologic outcome in survivors of childhood arterial ischemic stroke and sinovenous thrombosis. J Child Neurol 2000;15(5):316-24.
125. Koelfen W, Freund M, Konig S, Vamholt V, Rohr H, Schultze C. Results of parenchymal and angiographic magnetic resonance imaging and neuropsychological testing of children after stroke as neonates. Eur J Pediatr 1993;152(12):1030-5.
126. Carvalho KS, Bodensteiner JB, Connolly PJ, Garg BP. Cerebral venous thrombosis in children. J Child Neurol 2001;16(8):574-80.
127. Gunther G, Junker R, Strater R, et al. Symptomatic ischemic stroke in full-term neonates: role of acquired and genetic prothrombotic risk factors. Stroke 2000;31(10):2437-41.
128. Lynch JK, Nelson KB, Curry CJ, Grether JK. Cerebrovascular disorders in children with the factor V Leiden mutation. J Child Neurol 2001;16(10):735-44.
129. deVeber G, Andrew M. Canadian Pediatric Ischemic Stroke Registry. Analysis. Pediatr Res 1994;35:379A.
130. Kerr LM, Anderson DM, Thompson JA, Lyver SM, Call GK. Ischemic stroke in the young: evaluation and age comparison of patients six months to thirty-nine years. J Child Neurol 1993;8(3):266-70.
131. Achtman M. Global epidemiology of meningococcal disease. In: Cartwright K, editor. Meningococcal disease. Chicester, England: John Wiley; 1995. p. 159-75.
132. Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;345(6):408-16.
133. White B, Livingstone W, Murphy S, Hodgson A, Rafferty M, Smith O. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000;96:3719-24.
134. Goldhaber SZ. Pulmonary embolism. N Engl J Med 1998;339(2):93-104.
135. Anderson DR, Wells PS. Improvements in the diagnostic approach for patients with suspected deep vein thrombosis or pulmonary embolism. Thromb Haemost 1999;82(2):878-86.
136. Wells P, Anderson D, Ginsberg J. Assessment of deep vein thrombosis or pulmonary embolism by the combined use of clinical model and noninvasive diagnostic tests. Semin Thromb Hemost 2000;26(6):643-56.
137. Moser KM. Diagnosing pulmonary embolism. BMJ 1994;309(6968):1525-6.
138. Moser KM, Fedullo PF, LitteJohn JK, Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. JAMA 1994;271(3):223-5.
139. Rathbun SW, Raskob GE, Whitsett TL. Sensitivity and specificity of helical computed tomography in the diagnosis of pulmonary embolism: a systematic review. Ann Intern Med 2000; 132(3):227-32.
140. Coche EE, Hamoir XL, Hammer FD, Hainaut P, Goffette PP. Using dual-detector helical CT angiography to detect deep venous thrombosis in patients with suspicion of pulmonary embolism: diagnostic value and additional findings. AJR Am J Roentgenol 2001;176(4):1035-9.
141. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Application of a novel and rapid whole blood assay for D-dimer in patients with clinically suspected pulmonary embolism. Thromb Haemost 1995;73(1):35-8.
142. Ginsberg JS, Wells PS, Kearon C, et al. Sensitivity and specificity of a rapid whole-blood assay for D-dimer in the diagnosis of pulmonary embolism. Ann Intern Med 1998;129(12):1006-11.
143. Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000;83(3):416-20.
144. Greenfield LJ, Rutherford RB. Recommended reporting standards for vena caval filter placement and patient follow-up. Vena Caval Filter Consensus Conference. J Vasc Interv Radiol 1999;10(8):1013-9.
145. Linsenmaier U, Rieger J, Schenk F, Rock C, Mangel E, Pfeifer KJ. Indications, management, and complications of temporary inferior vena cava filters. Cardiovasc Intervent Radiol 1998; 21(6):464-9.
146. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998; 338(7):409-15.
147. Akesson H, Brudin L, Dahlstrom J, Eklof B, Ohlin P, Plate G. Venous function assessed during a 5 year period after acute ilio-femoral venous thrombosis treated with anticoagulation. Eur J Vasc Surg 1990;4(1):43-8.
148. Halliday P. Development of the post-thrombotic syndrome: its management at different stages. World J Surg 1990;14(5):703-10.
149. Walker R, Woodyer A, Dormandy J. Venous claudication. A report of 15 cases and a review of the literature. Int Angiol 1985;4(3):365-7.
150. Brandjes DP, Buller HR, Heijboer H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997;349(9054):759-62.
151. Hyers T, Agnelli G, Hull R, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119:176-193S.
152. Dix D, Andrew M, Marzinotto V, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000;136(4):439-45.
153. Massicotte MP. Low-molecular-weight heparin therapy in children. J Pediatr Hematol Oncol 2001;23(3):189-94.
154. Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995;74(1):415-25.
155. Andrew M, Brooker L, Leaker M, Paes B, Weitz J. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration. Thromb Haemost 1992;68(3):325-30.
156. Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001;134(3):191-202.
157. Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res 1994;35(1):78-83.
158. Hirsh J. Heparin. N Engl J Med 1991;324(22):1565-74.
159. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79(1):1-17.
160. Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med 1998;158(18):2001-3.
161. Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996;128(3):313-8.
162. Massicotte P, Leaker M, Marzinotto V, et al. Enhanced thrombin regulation during warfarin therapy in children compared to adults. Thromb Haemost 1998;80(4):570-4.
163. Andrew M, Michelson AD, Bovill E, Leaker M, Massicotte MP. Guidelines for antithrombotic therapy in pediatric patients. J Pediatr 1998;132(4):575-88.
164. Streif W, Andrew M, Marzinotto V, et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood 1999;94(9):3007-14.
165. Levy M, Benson LN, Burrows PE, et al. Tissue plasminogen activator for the treatment of thromboembolism in infants and children. J Pediatr 1991;118(3):467-72.
166. Hartmann J, Hussein A, Trowitzsch E, Becker J, Hennecke KH. Treatment of neonatal thrombus formation with recombinant tissue plasminogen activator: six years experience and review of the literature. Arch Dis Child Fetal Neonatal Ed 2001;85(1):F18-22.
167. Knofler R, Dinger J, Kabus M, et al. Thrombolytic therapy in children - clinical experiences with recombinant tissue-plasminogen activator. Semin Thromb Hemost 2001;27(2):169-74.
168. Manco-Johnson MJ, Nuss R, Hays T, Krupski W, Drose J, Manco-Johnson ML. Combined thrombolytic and anticoagulant therapy for venous thrombosis in children. J Pediatr 2000; 136(4):446-53.
169. Comerota AJ, Throm RC, Mathias SD, Haughton S, Mewissen M. Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life. J Vasc Surg 2000;32(1):130-7.
170. Arepally A, Hofmann LV, Kim HS, et al. Weight-based rt-PA thrombolysis protocol for acute native arterial and bypass graft occlusions. J Vasc Interv Radiol 2002;13(1):45-50.
171. Swischuk JL, Fox PF, Young K, et al. Transcatheter intraarterial infusion of rt-PA for acute lower limb ischemia: results and complications. J Vasc Interv Radiol 2001;12(4):423-30.
172. Chang R, Cannon III RO, Chen CC, et al. Daily catheter-directed single dosing of t-PA in treatment of acute deep venous thrombosis of the lower extremity. J Vasc Interv Radiol 2001; 12(2):247-52.
173. Sandbaek G, Staxrud LE, Rosen L, et al. Outcome after catheter-directed thrombolysis of occluded prosthetic femoropopliteal bypasses. A prospective study. Acta Radiol 2000;41(3):249-54.
174. Semba CP, Murphy TP, Bakal CW, Calis KA, Matalon TA. Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: review of the clinical literature. The Advisory Panel. J Vasc Interv Radiol 2000;11(2 Pt 1):149-61.
175. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345(18):1298-304.
176. Turpie AG. Looking forward in the treatment of deep-vein thrombosis. Semin Hematol 2001; 38(2 Suppl 5):49-57.
177. Turpie AG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001;344(9):619-25.
178. Gladwell T. Bivalirudin: a direct thrombin inhibitor. Clin Ther 2002;24(1):38-58.
179. Weitz J, Buller H. Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation 2002;105(8):1004-11.